← Back to all trials
Not Yet Recruiting
NCT07209267
Baricitinib Curative Repression of HIV-1
Conditions: HIV Infection, HIV
Sex: All
Ages: 18 Years – 70 Years
Healthy volunteers: Yes
Phase: PHASE2
Enrollment: 35
Sponsor: Emory University
Location: Grady Infectious Diseases Clinic (Ponce Center) Atlanta Georgia
Summary
This study is being done to test whether a drug called baricitinib, which blocks specific causes of inflammation, affects HIV-1 viral rebound and viral load levels after HIV treatment is discontinued. Researchers will test the effects of continuing baricitinib in people with HIV before and after discontinuing their antiretroviral therapy. This drug is approved by the Food and Drug Administration (FDA) for other diseases; it is not approved for the treatment of HIV-1. The study team will also investigate any side effects associated with the drug.
Eligibility Criteria
Inclusion Criteria:
* Documented HIV infection
* On continuous ART for at least 96 weeks before enrollment, with no interruption of ART for 7 consecutive days or longer in the 48 weeks before enrollment.
* Plasma HIV-1 RNA levels of \
Source: ClinicalTrials.gov (NCT07209267). StuddyBuddy aggregates publicly available trial information.
